Updated time: 2022-09-15 09:07:45
10A-1070301
TW I729363、US 11,357,788 B2
We discovered that decreasing lncRNA NEAT1 expression can disrupt TDP43 aggregation and rescue ALS motor neuron degeneration. This approach will lead to developing new therapeutic target for slowing ALS progression and preventing death of MNs.
Coupling iPSCs and CRISPR, we revealed that NEAT1 is a target for ALS drug development. Our platform is based on motor neurons derived from ALS patients iPSCs, which is the closest drug developing system to ALS patients. Ours finding and platform provide a proper target and platform to ALS treatment. In the future, time and costs can be saved for further ALS clinical trials.
Lowering NEAT1 expression is the target for ALS drug development. Meanwhile, our platform can be used for ALS drug screening and potentially cellular therapy. Also, lNEAT1 could potentially provide as a therapeutic target for other TDP43 associated neurodegenerative disease including Alzheimer’s disease and TDP43 associated frontotemporal dementia. Eventually, the process of our platform will be adapted for other neurodegenerative diseases and genetic diseases for drug development.
Hung-Chih Kuo, Yi-Ying Wu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Modeling amyotrophic lateral sclerosis (ALS) with iPSCs reveals potential role of LncRNA NEAT1 in TDP 43-associated disease path